NCT03330782

Brief Summary

Elderly patients show different pharmacokinetic and pharmacodynamic variables and usually need smaller doses of anesthetic drugs than younger patients. The purpose of this study was to investigate the optimal effect-site concentration of remifentanil for preventing injection pain during propofol induction in elderly patients by the Dixon's up-and-down method.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
52

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Nov 2017

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 30, 2017

Completed
7 days until next milestone

First Posted

Study publicly available on registry

November 6, 2017

Completed
10 days until next milestone

Study Start

First participant enrolled

November 16, 2017

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 15, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 15, 2018

Completed
Last Updated

July 5, 2019

Status Verified

July 1, 2019

Enrollment Period

7 months

First QC Date

October 30, 2017

Last Update Submit

July 2, 2019

Conditions

Keywords

painpropofolremifentanil

Outcome Measures

Primary Outcomes (1)

  • Severity of propofol injection pain-4 point scale

    0 = no pain (negative response to questioning), 1. = mild pain (pain reported only in response to questioning without any behavioral signs), 2. = moderate pain (pain reported in response to questioning and accompanied by a behavioral signs or pain reported spontane¬ously without questioning), 3. = severe pain (vocal response accompanied by facial grimacing, arm withdrawal, or tears)

    during 3 min after remifentanil and propofol infusion to reach the equilibrium of plasma and effect-site concentration

Study Arms (2)

Elderly

EXPERIMENTAL

Remifentanil was infused at predetermined effect-site concentration before propofol infusion in elderly patients.

Drug: Remifentanil

Adult

ACTIVE COMPARATOR

Remifentanil was infused at predetermined effect-site concentration before propofol infusion in adult patients.

Drug: Remifentanil

Interventions

Remifentanil was infused at predetermined effect-site concentration prior to propofol infusion (initial concentration: 3.0 ng/ml) in elderly patients (65-80 years)

Also known as: Ultiva
Elderly

Eligibility Criteria

Age19 Years - 80 Years
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • ASA physical status I or II undergoing general anesthesia

You may not qualify if:

  • neurologic disorder
  • psychologic disorder
  • vascular disorder
  • patients with chronic pain
  • difficulty in vascular access

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Jong Yeop Kim

Suwon, Gyeonggi-do, 443-721, South Korea

Location

MeSH Terms

Conditions

Pain

Interventions

Remifentanil

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

PropionatesAcids, AcyclicCarboxylic AcidsOrganic ChemicalsPiperidinesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Officials

  • Jong Yeop Kim

    Ajou University Hospital, Suwon, Gyeongki-do, South Korea, 443-721

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NON RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

October 30, 2017

First Posted

November 6, 2017

Study Start

November 16, 2017

Primary Completion

June 15, 2018

Study Completion

June 15, 2018

Last Updated

July 5, 2019

Record last verified: 2019-07

Locations